Business Context and Reporting Period
This Form 8-K filing by BridgeBio Oncology Therapeutics, Inc. (BBOT) reports on events occurring on June 16, 2026, specifically the Company's 2026 Annual Meeting of Stockholders. The filing details the departure of a director and the results of shareholder votes on director elections and the ratification of the independent auditor.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance events and voting results rather than financial performance.
Material Changes and Voting Results
Director Departure
Michelle Doig resigned as a member of the Board of Directors effective June 16, 2026, upon the completion of her term as a Class I director. The resignation was not due to any disagreement with the Company regarding operations, policies, or practices.
Shareholder Voting Summary
- Shares Entitled to Vote: 80,112,725
- Shares Present or Represented: 48,344,441
Proposal 1: Election of Directors
Stockholders elected two Class I directors to serve until the 2029 Annual Meeting:
| Director Nominee | Votes For | Votes Withheld |
|---|---|---|
| Peter Lebowitz, M.D., Ph.D. | 31,822,504 | 3,372 |
| Frank P. McCormick, Ph.D., F.R.S., D. Sc. | 25,654,119 | 6,171,757 |
Note: There were 2,713,439 broker non-votes and 13,805,126 no votes regarding this proposal.
Proposal 2: Ratification of Auditor
Stockholders ratified the appointment of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2026.
| Votes For | Votes Against | Abstentions |
|---|---|---|
| 34,535,875 | 3,440 | 0 |
Note: There were zero broker non-votes and 13,805,126 no votes regarding this proposal.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for guidance, outlook, management commentary on future strategy, specific risks, contingencies, or unusual items. The document is limited to reporting the outcomes of the Annual Meeting.
Key Facts for Investor Verification
- Verify the composition of the Board of Directors following the resignation of Michelle Doig and the election of Peter Lebowitz and Frank P. McCormick.
- Review the definitive proxy statement filed on April 28, 2026, for detailed biographies of the new directors and the rationale for the auditor ratification.
- Confirm the total number of shares outstanding and the percentage of shares represented at the meeting (approximately 60.3%) to assess shareholder engagement levels.
- Monitor the "no votes" count (13,805,126) which represents a significant portion of the voting power not cast for or against the proposals.